Japan's Takeda to offload generic drug venture with Israel's Teva

Japanese private equity firm J-Will to take over Teva Takeda Pharma

Takeda Pharmaceutical said it decided to divest its generic drug joint venture due to the evolving environment in Japan's drug industry. (Photo by Kohei Yamada)

HINAKO BANNO, Nikkei staff writer

December 7, 2024 01:24 JST

TOKYO -- Japanese drugmaker Takeda Pharmaceutical said Friday it will divest its generic drug joint venture with Israeli partner Teva Pharmaceutical Industries.

Takeda will unload its 49% stake in Teva Takeda Pharma, established in 2016, to Teva, which will then sell the unit to Japanese private equity firm J-Will Partners' subsidiary JKI.